This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination
and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
The primary objective is to evaluate lung function and exercise endurance time after 12 weeks
of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and
62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25
mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).